Literature DB >> 21938387

Determination of meloxicam using europium sensitized luminescence in the presence of co-luminescence reagents.

Salma Muhamed Z Al-Kindy1, Salim K Al-Habsy, Fakhr Eldin O Suliman, Haidar A J Al-Lawati.   

Abstract

A sensitive time-resolved luminescence method for the determination of meloxicam (MX) in methanol and in aqueous solution is described. The method is based on the luminescence sensitization of europium (Eu(3+)) by formation of ternary complex with MX in the presence of 1,10-phenanthroline as coligand, Tween-80 as surfactant and gadolinium ion as a co-luminescence reagent. The signal for Eu-MX-1,10-phenanthroline is monitored at λ(ex) = 360 nm and λ(em) = 620 nm. Optimum conditions for the formation of the complex in aqueous system were 0.01 M TRIS buffer, pH 8.0, 1,10-phenanthroline (6.0 × 10(-6) M), Gd(3+) (7.0 × 10(-6) M), Tween-80 (0.28%) and 1.75 mM of Eu(3+) which allows the determination of 20-800 ppb of MX with limit of detection (LOD) of 7 ppb. The relative standard deviations of the method range between 0.1 and 1.1% indicating excellent reproducibility of the method. The proposed method was successfully applied for the assay of MX in pharmaceutical formulations, plasma and in urine samples. Average recoveries of 99.8 ± 1.1%, 100.2 ± 0.9% and 100.9 ± 1.1% were obtained for MX in tablet, plasma and urine sample respectively.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21938387     DOI: 10.1007/s10895-011-0980-6

Source DB:  PubMed          Journal:  J Fluoresc        ISSN: 1053-0509            Impact factor:   2.217


  16 in total

1.  Electrochemical reduction of meloxicam at mercury electrode and its determination in tablets.

Authors:  A M Beltagi; M M Ghoneim; A Radi
Journal:  J Pharm Biomed Anal       Date:  2002-02-01       Impact factor: 3.935

2.  Spectrophotometric and fluorimetric methods for the determination of meloxicam in dosage forms.

Authors:  Ekram M Hassan
Journal:  J Pharm Biomed Anal       Date:  2002-02-01       Impact factor: 3.935

3.  LC determination and pharmacokinetics of meloxicam.

Authors:  Bhavesh Dasandi; H Saroj; K M Bhat
Journal:  J Pharm Biomed Anal       Date:  2002-06-01       Impact factor: 3.935

4.  Spectrophotometric methods for determining meloxicam in pharmaceuticals using batch and flow-injection procedures.

Authors:  M S García; C Sánchez-Pedreño; M I Albero; J Martí
Journal:  Eur J Pharm Sci       Date:  2000-01       Impact factor: 4.384

5.  Mechanism of interaction of the non-steroidal antiinflammatory drugs meloxicam and nimesulide with serum albumin.

Authors:  Neelam Seedher; Sonu Bhatia
Journal:  J Pharm Biomed Anal       Date:  2005-04-02       Impact factor: 3.935

Review 6.  Liquid chromatographic determination using lanthanides as time-resolved luminescence probes for drugs and xenobiotics: advantages and limitations.

Authors:  A Rieutord; P Prognon; F Brion; G Mahuzier
Journal:  Analyst       Date:  1997-05       Impact factor: 4.616

7.  Spectrofluorimetric and spectrophotometric stability-indicating methods for determination of some oxicams using 7-chloro-4-nitrobenz-2-oxa-1,3-diazole (NBD-Cl).

Authors:  Elham Anwer Taha; Nahla Nour Salama; Laila El-Sayed Abdel Fattah
Journal:  Chem Pharm Bull (Tokyo)       Date:  2006-05       Impact factor: 1.645

8.  A mass spectrometric study on meloxicam metabolism in horses and the fungus Cunninghamella elegans, and the relevance of this microbial system as a model of drug metabolism in the horse.

Authors:  Annica Tevell Aberg; Charlotte Olsson; Ulf Bondesson; Mikael Hedeland
Journal:  J Mass Spectrom       Date:  2009-07       Impact factor: 1.982

9.  Pharmacokinetics and metabolic pattern after intravenous infusion and oral administration to healthy subjects.

Authors:  J Schmid; U Busch; G Heinzel; G Bozler; S Kaschke; M Kummer
Journal:  Drug Metab Dispos       Date:  1995-11       Impact factor: 3.922

10.  A sequential injection method for the determination of piroxicam in pharmaceutical formulations using europium sensitized fluorescence.

Authors:  Salma M Z Al-Kindy; Aisha Al-Wishahi; Fakhr Eldin O Suliman
Journal:  Talanta       Date:  2004-12-15       Impact factor: 6.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.